Company intelligence / Profile preview

GCJBP

Ownership: Private
Development stage: Other

Overview

GCJBP Laennec Injection is a human placenta hydrolysate product containing various cytokines and bioactive molecules. It has been approved for improving liver function and has been prescribed for menopausal disorders, atopic dermatitis, skin care applications as well as for fatigue. Its mechanism of action is not fully understood but clinical studies suggest potential efficacy in chronic fatigue patients. A Phase 3 randomized controlled trial was completed to assess its safety and efficacy in this indication[2].

Therapeutic areas: NeurologyDermatologyGastroenterologyOtherWomen's Health
Modalities: Biological productsProteinPeptides
Industry: Biotech

Partnerships

Green Cross Co., Ltd. ("GC" or "GC Biopharma")—collaborator/distributor/manufacturer relationship indicated by co-branding as "GCJBP"[2].

Beyond the preview

Go deeper on GCJBP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCJBP.

Explore the full profile